Actuate Therapeutics Files Amended S-1/A Ahead of IPO
On October 19, 2026, Actuate Therapeutics filed an amended S-1/A registration statement (2 MB) with the SEC. The oncology-focused biotech disclosed preclinical data and early clinical progress in prior filings.
51CFO view：Biotech S-1/A updates often reflect clinical milestones or financing. The CFO must apply ASC 730 consistently for R&D expense capitalization and reconcile non-GAAP metrics (e.g., cash burn rate) to GAAP results in MD&A—a key factor for SEC’s assessment of going concern viability.
On October 19, 2026, Actuate Therapeutics filed an amended S-1/A registration statement (2 MB) with the SEC. The oncology-focused biotech disclosed preclinical data and early clinical progress in prior filings.
Source：SEC EDGAR · S-1 招股书备案
Why this matters to your CFO search
Where this touches your finance hire
Every listing event changes what you need from a CFO. Start from the step you are actually at.
What kind of CFO does a US IPO need?
S-1 / F-1 filing, US GAAP conversion, roadshow — the hard requirements.
Read →
Who owns SEC reporting and US GAAP?
Signature responsibility for 10-K / 10-Q / 8-K / 20-F, and common comments.
Read →
Who runs finance through a SPAC merger?
De-SPAC files F-1 / 424(b); merger audit and disclosure cadence differ.
Read →